The results of treatment in 100 patients with limited-stage small cell lung cancer
Related Experiment Video
Updated: Aug 7, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Background:
In an attempt to improve treatment results of small cell lung cancer (SCLC), combined induction chemotherapy and thoracic and prophylactic brain radiation therapy were administered.
Method:
From December 1980 to December 1987, 112 patients with limited-stage SCLC were treated with combination induction chemotherapy and thoracic or prophylactic brain radiation therapy; 100 were evaluable.
Results:
The complete response rate was 40%, and complete and partial responses totaled 94%, with a 5-year survival rate of 23%. There was no difference in remission and survival rates between three-drug and four-drug induction chemotherapeutic regimens. Six chemotherapeutic courses produced longer survival than less therapy. Although the occurrence of brain metastases was no different with or without prophylactic brain radiation therapy, the 3-year survival after this procedure was improved.
Conclusion:
Treatment of limited-stage SCLC with induction chemotherapy and thoracic and prophylactic brain radiation therapy produced improved remission and survival rates.